Gemcitabine Injection, Powder, Lyophilized, For Solution
Product Images NDC 16714-930

Description: This is a comparison of the median time to documented disease progression between two treatments: Gemcitabine For Injection/Paclitaxel and Paciitaxel. The median time to documented disease progression for Gemcitabine For Injection/Paclitaxel was 5.2 months, whereas for Paciitaxel it was 2.9 months. A Log rank test was performed, resulting in a p-value of less than 0.0001, indicating that the time to documented disease progression between the two treatments is significantly different. The graph shows the time to documented disease progression for both treatments over a period of 24 months.*

This is a table showing survival probability and survival time (in months) for a group of people who received the chemotherapy drugs Gemcitabine/Cisplatin and Cisplatin (262 people). No additional information is available in the text.*

This text appears to be a chart or graph displaying the survival times (in months) for a drug called "Gemctabin for injection" at various intervals. However, without more information, it is difficult to interpret the chart or provide any additional details about the drug or its efficacy.*

Beonhl is a cytotoxic agent packaged in a sterile single-dose vial. It contains 200mg of gemcitabine hydrochloride, 200mg of mannitol, and 20.73mg of sodium acetate trihydrate. The solution must be reconstituted and further diluted before being administered intravenously. The manufacturer warns against refrigerating the drug, and post-reconstitution, it should be stored at temperatures between 20°-25°C. The unused portion must be discarded after 24 hours. The drug is manufactured for Northstar Rx LLC, Memphis, TN by Kindos Pharmaceuticals Co., Ltd, Chengdu, Sichuan, PR, China.*

NDC16714-909-01 For Injection, USP 200mg/vial Cytotoxic Agent Sterile single-dose vial must be reconstituted and further diluted for intravenous use only, lyophilized. Each vial contains gemcitabine HCl USP equivalent to 200mg gemcitabine, 200mg mannitol, 2073mg sodium acetate trihydrate. It is sterile, non-pyrogenic, preservative-free, and the container closure is not made with natural rubber latex. This product requires caution, as gemcitabine hydrochloride has potential cytotoxic properties, and great care should be taken to prevent inhaling particles and exposure to the skin. Storage should be at 20° to 25°C. See accompanying literature for more information and instructions.*

This is a description for a medication called Gemcitabine HCl USP. The medication is available in the form of a sterile, single-dose vial containing 38mg/mL of solution. It also includes 1g mannitol, 103.5 mg sodium acetate, and hydrochloric acid and/or sodium hydroxide. The medication should not be refrigerated and should be stored at controlled room temperature prior to and after reconstitution. The medication should be discarded if not used within 24 hours of administration. The medication is manufactured by Kindos Pharmaceuticals Co. in China and distributed by Northstar Rx LLC in Tennessee.*

This is a description of a cytotoxic agent called Gemcitabine Hydrochloride, which is provided in a sterile single-dose vial. It is manufactured in China and distributed by Northstar Re LLC of Memphis, TN. The vial must be reconstituted and further diluted before it can be administered intravenously. Gemcitabine Hydrochloride is not to be refrigerated and should be kept at room temperature. The container is not made of natural rubber components, and caution should be taken to prevent inhaling particles. The preparation for intravenous solution is described in accompanying literature.*